$110,877,385
to MAPP BIOPHARMACEUTICAL, INC.
THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Develop MBP091, an immunotherapy treatment for Marburg virus infection, under a cost-plus-fixed-fee contract.
Addresses critical gap in medical countermeasures for a high-mortality viral hemorrhagic fever with pandemic potential.
Signals sustained demand for specialized biopharmaceutical manufacturing, viral immunology expertise, and clinical trial infrastructure.
U.S. investment in rare infectious disease therapeutics where China has limited competitive presence; demonstrates biodefense preparedness.
Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002285.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00076_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.